| Cashandra Shawon Hall, RN BSN | |
|
15 Suffern Place, Suffern, NY 10901 | |
| (845) 357-4500 | |
| (845) 357-5039 |
| Full Name | Cashandra Shawon Hall |
|---|---|
| Gender | Female |
| Speciality | Registered Nurse |
| Location | 15 Suffern Place, Suffern, New York |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1043872500 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 163W00000X | Registered Nurse | 756460 (New York) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Cashandra Shawon Hall, RN BSN 15 Suffern Place, Suffern, NY 10901 Ph: (845) 357-4500 | Cashandra Shawon Hall, RN BSN 15 Suffern Place, Suffern, NY 10901 Ph: (845) 357-4500 |
News Archive
In this post in the Public Health Institute's "Dialogue4Health" blog, Jeffrey Meer, director of PHI's Washington-based advocacy on global health, writes that "a significant expansion of PEPFAR's existing work to combat cervical cancer" through a partnership with the George W. Bush Institute known as Pink Ribbon Red Ribbon (PRRR); a 50 percent increase in the U.S. government's "commitment to screen and treat for this type of cancer from $20 million over five years to $30 million"; and additional funding from Susan G. Komen for the Cure "to expand breast cancer awareness and prevention among the same target population of women receiving care at PEPFAR-funded HIV service sites" has allowed "the wonderfully robust PEPFAR prevention and treatment platform, considered one of the great global health achievements in recent times, to be made available to a whole new type of prevention - in this case for a non-communicable disease (NCD)."
California and Arizona researchers have identified a gene variant that carries nearly twice the risk of developing an increasingly common type of blood cancer, according to a study published online today by the science journal Nature Genetics.
The drug eculizumab, a synthetic antibody that inhibits the inflammatory response, significantly reduced the risk of relapse with neuromyelitis optica spectrum disorder.
Zydus Cadila, a global healthcare provider and one of India's leading healthcare companies has received Phase I clinical trial permission from the DCGI for ZYOG1 - a novel GLP-1 agonist. Designed and developed at the Zydus Research Centre using a unique platform technology, ZYOG1 is a novel, oral, anti-diabetic molecule.
For some Canadians, any cut such as from dental work or surgery can cause days or more of bleeding. Although they are not hemophiliacs, for some an ordinary bruise can balloon into the size of an orange.
› Verified 5 days ago
Lavinia Locust, RN Registered Nurse Medicare: Not Enrolled in Medicare Practice Location: 99 Washington Ave, Suffern, NY 10901 Phone: 845-357-4500 Fax: 845-357-5039 | |
Rebecca Klein, Registered Nurse Medicare: Not Enrolled in Medicare Practice Location: 5 Samego Ct, Suffern, NY 10901 Phone: 845-641-0297 | |
Davinder Kaur, RN Registered Nurse Medicare: Not Enrolled in Medicare Practice Location: 99 Washington Ave, Suffern, NY 10901 Phone: 845-357-4500 | |
Meggon Keyaira Vickers, RN Registered Nurse Medicare: Not Enrolled in Medicare Practice Location: 15 Suffern Place, Suffern, NY 10901 Phone: 845-357-4500 | |
Daniela Brickhouse, RN Registered Nurse Medicare: Not Enrolled in Medicare Practice Location: 99 Washington Ave, Suffern, NY 10901 Phone: 845-357-4500 Fax: 845-357-5039 | |
Rebecca A. Mierop, RN BSN Registered Nurse Medicare: Not Enrolled in Medicare Practice Location: 99 Washington Ave, Suffern, NY 10901 Phone: 845-357-4500 | |
Danielle Teresa Kunak, BSN, RN Registered Nurse Medicare: Not Enrolled in Medicare Practice Location: 15 Suffern Place, Suffern, NY 10901 Phone: 845-357-4500 Fax: 845-357-5039 |